IDEXX Laboratories (IDXX) vs Lantheus (LNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lantheus (LNTH) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 93.2% versus a loss of 18.5%. Over five years, LNTH leads with a +330.7% price change compared with -19.2% for IDXX. IDEXX Laboratories is the larger company by market cap ($40.43 billion vs $6.54 billion), about 6.2 times the size.
On valuation, Lantheus trades at a lower forward P/E (15.7x vs 30.7x for IDEXX Laboratories). IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus 15.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | LNTH |
|---|---|---|
| Share price | $513.14 | $100.12 |
| Market cap | $40.43B | $6.54B |
| 1-day change | +1.28% | -0.06% |
| YTD return | -24.15% | +50.53% |
| 1-year return | -18.54% | +93.25% |
| 5-year return | -19.21% | +330.70% |
| P/E ratio (TTM) | 36.06 | 24.24 |
| Forward P/E | 30.66 | 15.70 |
| EPS (TTM) | $14.23 | $4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $1.54B |
| Revenue growth (YoY) | +10.42% | +0.50% |
| Net income (latest FY) | $1.06B | $233.56M |
| Gross margin | 61.80% | 61.10% |
| Operating margin | 31.60% | 20.16% |
| Net margin | 24.62% | 15.15% |
| 52-week high | $769.98 | $111.86 |
| 52-week low | $500.61 | $50.16 |
| Distance from 52-week high | -33.36% | -10.50% |
| Analyst consensus | buy | none |
| Avg. price target upside | +36.67% | +7.61% |
| Average volume | 553.95K | 1.32M |
| Shares outstanding | 78.78M | 65.30M |
| Employees | 11,000 | 1,193 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 6.2 times larger than Lantheus by market value ($40.43B vs $6.54B).
- LNTH has outperformed IDXX by 111.8 percentage points over the past year.
- IDEXX Laboratories trades at a higher earnings multiple (36.1x vs 24.2x trailing P/E).
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus 15.2 cents for Lantheus.
- IDEXX Laboratories grew revenue faster in its latest fiscal year (+10.42% vs +0.50%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
IDXX vs LNTH FAQ
Which is bigger, IDEXX Laboratories or Lantheus?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.43B compared with $6.54B for Lantheus (LNTH).
Which stock has performed better over the past year, IDXX or LNTH?
LNTH returned +93.25% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IDXX or LNTH?
LNTH has the lower trailing P/E at 24.2, versus 36.1 for IDXX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are IDEXX Laboratories and Lantheus in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.